|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.75 USD | +1.62% |
|
-6.62% | -10.15% |
| 30/06 | CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell Small Cap Comp Growth Benchmark | CI |
| 30/06 | CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell 2500 Growth Benchmark | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 91Cr | 11.98L | 37Cr | 3.73Cr | 35.1L | |||||
Total Revenues | 91Cr | 11.98L | 37Cr | 3.73Cr | 35.1L | |||||
Cost of Goods Sold, Total | 44Cr | 57Cr | 52Cr | 43Cr | 50Cr | |||||
Gross Profit | 48Cr | -57Cr | -15Cr | -39Cr | -49Cr | |||||
Selling General & Admin Expenses, Total | 10Cr | 10Cr | 7.62Cr | 7.3Cr | 7.35Cr | |||||
Other Operating Expenses, Total | 10Cr | 10Cr | 7.62Cr | 7.3Cr | 7.35Cr | |||||
Operating Income | 37Cr | -67Cr | -22Cr | -47Cr | -57Cr | |||||
Interest Expense, Total | - | - | - | - | - | |||||
Interest And Investment Income | 60.03L | 2.27Cr | 7.18Cr | 10Cr | - | |||||
Net Interest Expenses | 60.03L | 2.27Cr | 7.18Cr | 10Cr | - | |||||
Income (Loss) On Equity Invest. | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | - | - | - | - | 8.66Cr | |||||
EBT, Excl. Unusual Items | 38Cr | -65Cr | -15Cr | -36Cr | -48Cr | |||||
In Process R&D Expenses | - | - | - | - | -9.63Cr | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 38Cr | -65Cr | -15Cr | -36Cr | -58Cr | |||||
Income Tax Expense | 18.7L | -3L | 28.88L | 35.87L | 36.34L | |||||
Earnings From Continuing Operations | 38Cr | -65Cr | -15Cr | -37Cr | -58Cr | |||||
Net Income to Company | 38Cr | -65Cr | -15Cr | -37Cr | -58Cr | |||||
Minority Interest | - | - | - | - | - | |||||
Net Income - (IS) | 38Cr | -65Cr | -15Cr | -37Cr | -58Cr | |||||
Net Income to Common Incl Extra Items | 38Cr | -65Cr | -15Cr | -37Cr | -58Cr | |||||
Net Income to Common Excl. Extra Items | 38Cr | -65Cr | -15Cr | -37Cr | -58Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 4.97 | -8.36 | -1.94 | -4.34 | -6.47 | |||||
Basic EPS - Continuing Operations | 4.97 | -8.36 | -1.94 | -4.34 | -6.47 | |||||
Basic Weighted Average Shares Outstanding | 7.59Cr | 7.77Cr | 7.92Cr | 8.44Cr | 8.99Cr | |||||
Net EPS - Diluted | 4.7 | -8.36 | -1.94 | -4.34 | -6.47 | |||||
Diluted EPS - Continuing Operations | 4.7 | -8.36 | -1.94 | -4.34 | -6.47 | |||||
Diluted Weighted Average Shares Outstanding | 8.04Cr | 7.77Cr | 7.92Cr | 8.44Cr | 8.99Cr | |||||
Normalized Basic EPS | 3.12 | -5.23 | -1.19 | -2.69 | -3.35 | |||||
Normalized Diluted EPS | 2.95 | -5.23 | -1.19 | -2.69 | -3.35 | |||||
Supplemental Items | ||||||||||
EBITDA | 39Cr | -65Cr | -20Cr | -45Cr | -55Cr | |||||
EBITA | 37Cr | -67Cr | -22Cr | -47Cr | -57Cr | |||||
EBIT | 37Cr | -67Cr | -22Cr | -47Cr | -57Cr | |||||
EBITDAR | 43Cr | -60Cr | -16Cr | -41Cr | -51Cr | |||||
Total Revenues (As Reported) | 91Cr | 11.98L | 37Cr | 3.73Cr | 35.1L | |||||
Effective Tax Rate - (Ratio) | 0.49 | 0.05 | -1.92 | -0.99 | -0.63 | |||||
Current Domestic Taxes | - | - | - | - | - | |||||
Current Foreign Taxes | - | - | - | - | - | |||||
Total Current Taxes | 1L | 7L | 33.12L | 40.71L | 27.19L | |||||
Deferred Domestic Taxes | - | - | - | - | - | |||||
Total Deferred Taxes | 17.48L | -10.1L | -4L | -5L | 9L | |||||
Normalized Net Income | 24Cr | -41Cr | -9.42Cr | -23Cr | -30Cr | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 10Cr | 10Cr | 7.62Cr | 7.3Cr | 7.35Cr | |||||
Research And Development Expense From Footnotes | 44Cr | 46Cr | 39Cr | 32Cr | 28Cr | |||||
Net Rental Expense, Total | 3.68Cr | 4.76Cr | 4.01Cr | 3.62Cr | 3.65Cr | |||||
Stock-Based Comp., COGS (Total) | 5.97Cr | 5.4Cr | 4.64Cr | 4.79Cr | 3.44Cr | |||||
Stock-Based Comp., G&A Exp. (Total) | 4.27Cr | 4.4Cr | 3.47Cr | 3.86Cr | 3.81Cr | |||||
Total Stock-Based Compensation | 10Cr | 9.79Cr | 8.1Cr | 8.66Cr | 7.25Cr |
- Stock Market
- Stocks
- CRSP Stock
- Financials CRISPR Therapeutics AG
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















